Metis TechBio Inks Up to $1.1 Billion Deal With Eli Lilly for Drug Delivery Tech

3-line summary

• Hong Kong-listed Metis TechBio signed a collaboration agreement with Eli Lilly for research and development of tissue-specific drug delivery technologies, with a total deal value of up to $1.1 billion; the article did not specify upfront payment, milestone terms, or payment structure, only the aggregate cap.
• No specific timeline or further details on the collaboration's duration were given in the article.

This summary is our own processing of the source article; see the source link below for full context.